The GLP-1 weekly formulation can greatly reduce the frequency of dosing, reduce gastrointestinal adverse effects, and increase the stability of the drug and improve patient compliance, which will provide a new treatment option for most Chinese patients with T2DM (Zhou et al., 2019). This evidence concerns the gene GLP1R and type 2 diabetes mellitus.